Mark Pruzanski
Impact in
- Hepatology top 0.5%
- Liver Diseases and Immunity
- Liver physiology and pathology
- Oncology top 1%
- Drug Transport and Resistance Mechanisms
Papers in
- Oncology 11
- Drug Transport and Resistance Mechanisms 11
-
- Liver physiology and pathology 3
- Liver Diseases and Immunity 3
- Co-authors
- Roberto Pellicciari (10 shared papers)Kristina Schoonjans (4 shared papers)Johan H. Auwerx (4 shared papers)Charles Thomas (4 shared papers)Luciano Adorini (11 shared papers)Antonio Macchiarulo (5 shared papers)Antimo Gioiello (4 shared papers)Giovanni Rizzo (4 shared papers)
- Journals
- Journal of Hepatology (3 papers)Journal of Pharmacology and Experimental Therapeutics (3 papers)ACS Medicinal Chemistry Letters (2 papers)Diabetes (2 papers)Nature Biotechnology (2 papers)
- Partner nations
- United StatesItalySwitzerland
In The Last Decade
Mark Pruzanski
23 papers receiving 6.6k citations
Mark Pruzanski's Hit Papers
Peers
Comparison fields: 5 of 93
- Hepatology 1.2k
- Oncology 1.9k
- Epidemiology 1.2k
- Nephrology 334
- Molecular Biology 1.8k
Countries citing papers authored by Mark Pruzanski
This map shows the geographic impact of Mark Pruzanski's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Pruzanski with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Pruzanski more than expected).
Fields of papers citing papers by Mark Pruzanski
This network shows the impact of papers produced by Mark Pruzanski. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Pruzanski. The network helps show where Mark Pruzanski may publish in the future.
Co-authors
The 25 scholars most cited alongside Mark Pruzanski, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 26 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | TGR5-Mediated Bile Acid Sensing Controls Glucose Homeostasis Hit paper breakdown → | 2009 | 1588 |
| 2 | Targeting bile-acid signalling for metabolic diseases Hit paper breakdown → | 2008 | 1192 |
| 3 | A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis Hit paper breakdown → | 2016 | 919 |
| 4 | Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease Hit paper breakdown → | 2013 | 825 |
| 5 | 2009 | 236 | |
| 6 | 2012 | 226 | |
| 7 | 2017 | 196 | |
| 8 | 2013 | 195 | |
| 9 | 2005 | 177 | |
| 10 | 2010 | 174 | |
| 11 | 2005 | 168 | |
| 12 | 2010 | 164 | |
| 13 | 2005 | 163 | |
| 14 | 2009 | 158 | |
| 15 | 2014 | 142 | |
| 16 | 2017 | 57 | |
| 17 | 2011 | 53 | |
| 18 | 2012 | 38 | |
| 19 | 2013 | 37 | |
| 20 | 2012 | 34 |
About Mark Pruzanski
Mark Pruzanski is a scholar working on Oncology, Hepatology, Nephrology, Computational Theory and Mathematics and Epidemiology, having authored 26 papers that have together received 6.8k indexed citations. Recurring topics across this work include Drug Transport and Resistance Mechanisms (11 papers), Chronic Kidney Disease and Diabetes (4 papers), Liver physiology and pathology (3 papers), Liver Disease Diagnosis and Treatment (3 papers), Liver Diseases and Immunity (3 papers), Computational Drug Discovery Methods (3 papers), Cholesterol and Lipid Metabolism (2 papers) and Natural product bioactivities and synthesis (2 papers). The work is most often cited by research in Hepatology (1.2k citations), Oncology (1.9k citations), Epidemiology (1.2k citations), Nephrology (334 citations) and Molecular Biology (1.8k citations). Mark Pruzanski has collaborated with scholars based in United States, Italy and Switzerland. Frequent co-authors include Roberto Pellicciari, Kristina Schoonjans, Johan H. Auwerx, Charles Thomas, Luciano Adorini, Antonio Macchiarulo, Antimo Gioiello, Giovanni Rizzo, Julien Oury and Chikage Mataki. Their work appears in journals such as Journal of Hepatology, Journal of Pharmacology and Experimental Therapeutics, ACS Medicinal Chemistry Letters, Diabetes and Nature Biotechnology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.